A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for the Treatment of Recurrent or Persistent Endometrial Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2016
At a glance
- Drugs Apitolisib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Acronyms MAGGIE study
- Sponsors Genentech
- 07 Sep 2016 Results published in the Cancer.
- 22 Jul 2014 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.
- 20 Aug 2013 Planned End Date changed from 1 Dec 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.